Search Blog
December 2013
« Nov   Jan »


pSivida Corp – Value Drivers – The Road Forward for pSivida


By Market Exclusive

pSivida Corp (NASDAQ:PSDV) today
published a new blog post on The Chairman’s Blog, written by the
company’s President and CEO, Dr. Paul Ashton.
is an exclusive online media publication that enables key executive
officers a unique platform to share insights about their company and
industry trends.

Dr. Ashton updates stakeholders on
pSivida’s product pipeline and its plans to move forward as a
Specialty Pharma company. He expresses his optimism for the company’s
product Medidur for posterior uveitis stating, “Medidur is a
sustained release micro-insert that delivers the same drug,
fluocinolone acetonide, as the FDA approved Retisert (which we
successfully developed with Bausch and Lomb). Retisert was approved
by the FDA for uveitis affecting the posterior segment of the eye,
the same indication we’ll be seeking for Medidur.” Read the full
blog post from Dr. Paul Ashton on

About pSivida Corp.

pSivida Corp., headquartered in
Watertown, MA, develops tiny, sustained release, drug delivery
products designed to deliver drugs at a controlled and steady rate
for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology
systems, Durasert™ and BioSilicon™, including Tethadur™. The
injectable, sustained release micro-insert ILUVIEN® for the
treatment of chronic Diabetic Macular Edema (DME) considered
insufficiently responsive to available therapies, licensed to Alimera
Sciences, Inc., is marketed in the U.K. and Germany and has also
received marketing authorization in Austria, France, Portugal, and
Spain and is awaiting authorization in Italy. pSivida has instituted
the first of two planned pivotal Phase III clinical trials for
Medidur™ for the treatment of posterior uveitis, a chronic
back-of-the-eye disease. An investigator-sponsored clinical trial is
ongoing for an injectable, bioerodible micro-insert to treat glaucoma
and ocular hypertension, a product candidate on which Pfizer Inc. has
an option. pSivida’s FDA-approved Retisert®, licensed to Bausch &
Lomb Incorporated, provides long-term, sustained drug delivery to
treat posterior uveitis.

About is an exclusive,
online media publication where publically and privatively held firms
alike share insights about their companies and industries. enables upper tier management to discuss issues
that are of importance to their stakeholders, shareholders, and
interested parties in an informal environment. In addition to
management`s insightful blog posts, staff and
aggregate partners contribute articles on finance, technology,
health, and energy while providing updated market trends, news, and